Advanced US proton therapy system to treat cancer at new Australian medical facility
23 Jun 2020
US-based ProTom International will install its Radiance 330® Proton Therapy System at the new Australian Bragg Centre.
Based in Adelaide, South Australia, the A$500 million centre will be the first clinically dedicated proton therapy centre in Australia and the Southern Hemisphere to deliver advanced precision radiation treatment. The Centre is expected to be completed in late 2023, with the first patients to be treated approximately 18 months later.
The project is supported by a A$68 million grant from the Australian Government and A$47.4 million from the South Australian Government.
Protom International is a leading device manufacturer of proton therapy technology. The company is based in Flower Mound, Texas, and Wakefield, Massachusetts, and installed its first proton therapy system in Massachusetts General Hospital.
‘We believe our Radiance 330 device is the world leader in proton therapy and will enhance the Bragg Centre’s position in cancer treatment not only in Australia, but across the Asia-Pacific region,’ says Stephen Spotts, Chief Executive Officer of ProTom International.
The precise nature of proton therapy allows radiation oncologists to target cancerous tissues directly with minimal damage to surrounding healthy tissue. This makes it a valuable treatment option for tumours close to vital organs or those diagnosed in children.
The Australian Bragg Centre is a purpose-built facility to be established within the South Australian Health and Medical Research Institute (SAHMRI) in Adelaide. Work has commenced on the centre, to be located within a new building in the A$3.6 billion Adelaide Bio Med City.
The Centre will be situated alongside the new Royal Adelaide Hospital, SAHMRI’s existing building, the University of Adelaide Health and Medical Sciences Building, and the University of South Australia’s Health Innovation Building.
Once fully operational, the centre can treat approximately 600–700 patients per year from Australia and across the Asia-Pacific region, with around half of these expected to be children and young adults.
Find out more about investing in Australia.